While this study needs to be regarded as a pilot study due to the lack of statistical power, the use of a retrospective cohort, and the inability to query C- and N-terminal truncations together, it highlights how p53 isoform IHC analysis may provide a source of prognostic biomarkers that have been thus far lacking in melanoma and might, once fully validated, aid the decision-making process for treating oncologists and melanoma patients. This evidence concerns the gene TP53 and melanoma.